22324 Federal Register / Vol. 77, No. 72 / Friday, April 13, 2012 / Notices 

contained in their draft International 

Classification for Patient Safety (ICPS). 

Commenting on Common Formats 

Hospital 1.2 

To allow for greater participation by 

the private sector in the subsequent 

development of the Common Formats, 

AHRQ engaged the NQF, a non-profit 

organization focused on health care 

quality, to solicit comments and advice 

to guide the further refinement of the 

Common Formats. The NQF then 

convenes an expert panel to review the 

comments received and provide 

feedback. The NQF began this process 

with feedback on AHRQ’s 0.1 Beta 

release of the Common Formats in 2008. 

Based upon the expert panel’s feedback, 

AHRQ, in conjunction with the PSWG, 

revises and refines the Common 

Formats. 

The Agency is specifically interested 

in obtaining feedback from both the 

private and public sectors on the new 

Common Formats—Hospital Version 1.2 

to guide the improvement of the 

formats. Information on how to 

comment and provide feedback on the 

Common Formats—Hospital Version 

1.2, is available at the NQF Web site for 

Common Formats: http:// 

www.Quality.forum.ORG/projects/ 

commonformats.aspx. 

The process for updating and refining 

the formats will continue to be an 

iterative one. Future versions of the 

Common Formats will be developed for 

ambulatory settings, such as ambulatory 

surgery centers and physician and 

practitioner offices. More information 

on the Common Formats can be 

obtained through AHRQ’s PSO Web site: 

http://www.PSO.AHRQ.gov/index.html. 

Dated: April 5, 2012. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 2012–8743 Filed 4–12–12; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Correction—Solicitation for 

Nominations for Members of the U.S. 

Preventive Services Task Force 

(USPSTF) 

The original date of publication for 

this Federal Register notice was March 

28, 2012, Volume 77, Number 60, pages 

18823–18825. On this publication, 

Gloria Washington’s email address is 

incorrect in two places of page 18824 

under subheadings ADDRESSES: and FOR

FURTHER INFORMATION CONTACT:. The 

correct email address for Gloria 

Washington is: USPSTFmember

nominations@AHRQ.HHS.GOV 

Dated: April 4, 2012. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 2012–8737 Filed 4–12–12; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Scientific Information Request on 

Treatment of Tinnitus 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Request for scientific 

information submissions. 

SUMMARY: The Agency for Healthcare 

Research and Quality (AHRQ) is seeking 

scientific information submissions from 

manufacturers of cochlear implants, 

sound masking devices, hearing aids, 

and transcranial magnetic stimulation 

medical devices. Scientific information 

is being solicited to inform our 

Comparative Effectiveness Review of 

Evaluation and Treatment of Tinnitus, 

which is currently being conducted by 

the Evidence-based Practice Centers for 

the AHRQ Effective Health Care 

Program. Access to published and 

unpublished pertinent scientific 

information on this device will improve 

the quality of this comparative 

effectiveness review. AHRQ is 

requesting this scientific information 

and conducting this comparative 

effectiveness review pursuant to Section 

1013 of the Medicare Prescription Drug, 

Improvement, and Modernization Act of 

2003, Public Law 108–173. 

DATES: Submission Deadline on or 

before May 14, 2012. 

ADDRESSES: Online submissions: 

http://effectivehealthcare.AHRQ.gov/ 

index.cfm/submitscientific-informationpackets/. Please select the study for 

which you are submitting information 

from the list of current studies and 

complete the form to upload your 

documents. 

Email submissions: 

ehcsrc@ohsu.edu (please do not send 

zipped files—they are automatically 

deleted for security reasons). 

Print submissions: Robin Paynter, 

Oregon Health and Science University, 

Oregon Evidence-based Practice Center, 

3181 SW Sam Jackson Park Road, Mail 

Code: BICC, Portland, OR 97239–3098. 

FOR FURTHER INFORMATION CONTACT: 

Robin Paynter, Research Librarian, 

Telephone: 503–494–0147 or Email: 

ehcsrc@ohsu.edu. 

SUPPLEMENTARY INFORMATION: In 

accordance with Section 1013 of the 

Medicare Prescription Drug, 

Improvement, and Modernization Act of 

2003, Public Law 108–173, the Agency 

for Healthcare Research and Quality has 

commissioned the Effective Health Care 

(EHC) Program Evidence-based Practice 

Centers to complete a comparative 

effectiveness review of the evidence for 

evaluation and treatment of tinnitus. 

The EHC Program is dedicated to 

identifying as many studies as possible 

that are relevant to the questions for 

each of its reviews. In order to do so, we 

are supplementing the usual manual 

and electronic database searches of the 

literature by systematically requesting 

information (e.g., details of studies 

conducted) from medical device 

industry stakeholders through public 

information requests, including via the 

Federal Register and direct postal and/ 

or online solicitations. We are looking 

for studies that report on treatment of 

tinnitus, including those that describe 

adverse events, as specified in the key 

questions detailed below. The entire 

research protocol, including the key 

questions, is also available online at: 

http://www.effectivehealthcare.AHRQ.

gov/index.cfm/search-for-guidesreviews-and-reports/?pageaction=

displayproduct&productid=811#4755. 

This notice is a request for industry 

stakeholders to submit the following: 

• A current product label, if 

applicable (preferably an electronic PDF 

file). 

• Information identifying published 

randomized controlled trials and 

observational studies relevant to the 

clinical outcomes. Please provide both a 

list of citations and reprints if possible. 

• Information identifying 

unpublished randomized controlled 

trials and observational studies relevant 

to the clinical outcomes. If possible, 

please provide a summary that includes 

the following elements: study number, 

study period, design, methodology, 

indication and diagnosis, proper use 

instructions, inclusion and exclusion 

criteria, primary and secondary 

outcomes, baseline characteristics, 

number of patients screened/eligible/ 

enrolled/lost to withdrawn/follow-up/ 

analyzed, and effectiveness/efficacy and 

safety results. 

• Registered ClinicalTrials.gov 

studies. Please provide a list including 

the ClinicalTrials.gov identifier, 

condition, and intervention. 

Your contribution is very beneficial to 

this program. AHRQ is not requesting 


pmangrum on DSK3VPTVN1PROD with NOTICES